Rejuvenate Bio

Rejuvenate Bio is a biotechnology company developing gene therapies to treat chronic and age-related diseases. The company’s pipeline includes RJB-0402, a liver-directed FGF21 therapy for metabolic diseases, along with RJB-01, RJB-02, and RJB-03 programs. Rejuvenate Bio initially focused on veterinary applications, developing gene therapy treatments for canine age-related conditions, before translating its platform to human therapeutics. The company leverages adeno-associated virus (AAV) gene therapy technology to deliver therapeutic genes that address underlying causes of age-related decline, including cardiac, metabolic, and renal diseases. Founded in 2018 and headquartered in San Diego, California, Rejuvenate Bio has raised approximately $34 million in Series A funding. Investors include KdT Ventures, Digitalis Ventures, VCapital, Merck Animal Health, CIRM, Connecticut Innovations, and Companion Fund. The company operates at the intersection of genomics, gene therapy, and metabolic disease treatment, with a team of approximately 16 employees.